Cargando…

Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status

BACKGROUND: Both cervical cancer and human immunodeficiency virus (HIV) are major public health problems in Sub-Saharan Africa. The objectives of the study were to investigate human papillomavirus (HPV) prevalence according to age, HIV status and gender. METHODS: Participants were 208 HIV-negative w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mbulawa, Zizipho Z A, Coetzee, David, Williamson, Anna-Lise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624185/
https://www.ncbi.nlm.nih.gov/pubmed/26502723
http://dx.doi.org/10.1186/s12879-015-1181-8
_version_ 1782397791263260672
author Mbulawa, Zizipho Z A
Coetzee, David
Williamson, Anna-Lise
author_facet Mbulawa, Zizipho Z A
Coetzee, David
Williamson, Anna-Lise
author_sort Mbulawa, Zizipho Z A
collection PubMed
description BACKGROUND: Both cervical cancer and human immunodeficiency virus (HIV) are major public health problems in Sub-Saharan Africa. The objectives of the study were to investigate human papillomavirus (HPV) prevalence according to age, HIV status and gender. METHODS: Participants were 208 HIV-negative women, 278 HIV-positive women, 325 HIV-negative men and 161 HIV-positive men between the ages of 18–66 years. HPV types were determined in cervical and penile cells by Roche Linear Array HPV genotyping assay. RESULTS: HPV prevalence was 36.7 % (76/207; 95 % confidence intervals (CI): 30.4–43.4 %) in HIV-negative women, with the highest prevalence of 61.0 % (25/41; 95 % CI: 45.7–74.4 %) in women aged 18–25 years. HPV prevalence was 74.0 % (205/277; 95 % CI: 68.5–78.8 %) in HIV-positive women, with the highest prevalence of 86.4 % (38/44; 95 % CI: 72.9–94.0 %) in women aged 18–25 years. HPV prevalence was found to decrease with increasing age in HIV-negative women (P = 0.0007), but not in HIV-positive women (P = 0.898). HPV prevalence was 50.8 % (159/313; 95 % CI: 45.3–56.3 %) in HIV-negative men, with the highest prevalence of 77.0 % (27/35; 95 % CI: 60.7–88.2 %) in men aged 18–25 years. HPV prevalence was 76.6 % (121/158; 95 % CI: 69.2–82.9 %) in HIV-positive men, with the highest prevalence of 87.5 % (7/8; 95 % CI: 50.8–99.9 %) in men 18–25 years of age. HPV prevalence was found to decrease with increasing age in HIV-negative men (P = 0.004), but not in HIV-positive men (P = 0.385). HIV-positive women had a significantly higher prevalence of one or more HPV type(s) in the bivalent (HPV-16/18: 20 % 55/277, 9 % 12/207; P <0.001), quadrivalent (HPV-6/11/16/18: 26 % 71/277, 12 % 24/207; P = 0.001) and nonavalent vaccine (HPV-6/11/16/18/31/33/52/56/58: 65 % 181/277, 24 % 50/207; P <0.001) compared to HIV-negative women. Similar observation were observed in men for bivalent (20 % 32/158, 10 % 30/313; P = 0.001), quadrivalent (35 % 56/158, 13 % 41/313; P <0.001) and nonavalent vaccine (75 % 119/158, 28 % 87/313; P <0.001). CONCLUSIONS: This study demonstrated high HPV prevalence among HIV-positive women and men in all age groups. The high prevalence of HPV types found in bivalent, quadrivalent and nonavalent vaccines in South African HIV-positive and HIV-negative women and men demonstrate that this population will greatly benefit from current HPV vaccines.
format Online
Article
Text
id pubmed-4624185
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46241852015-10-29 Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status Mbulawa, Zizipho Z A Coetzee, David Williamson, Anna-Lise BMC Infect Dis Research Article BACKGROUND: Both cervical cancer and human immunodeficiency virus (HIV) are major public health problems in Sub-Saharan Africa. The objectives of the study were to investigate human papillomavirus (HPV) prevalence according to age, HIV status and gender. METHODS: Participants were 208 HIV-negative women, 278 HIV-positive women, 325 HIV-negative men and 161 HIV-positive men between the ages of 18–66 years. HPV types were determined in cervical and penile cells by Roche Linear Array HPV genotyping assay. RESULTS: HPV prevalence was 36.7 % (76/207; 95 % confidence intervals (CI): 30.4–43.4 %) in HIV-negative women, with the highest prevalence of 61.0 % (25/41; 95 % CI: 45.7–74.4 %) in women aged 18–25 years. HPV prevalence was 74.0 % (205/277; 95 % CI: 68.5–78.8 %) in HIV-positive women, with the highest prevalence of 86.4 % (38/44; 95 % CI: 72.9–94.0 %) in women aged 18–25 years. HPV prevalence was found to decrease with increasing age in HIV-negative women (P = 0.0007), but not in HIV-positive women (P = 0.898). HPV prevalence was 50.8 % (159/313; 95 % CI: 45.3–56.3 %) in HIV-negative men, with the highest prevalence of 77.0 % (27/35; 95 % CI: 60.7–88.2 %) in men aged 18–25 years. HPV prevalence was 76.6 % (121/158; 95 % CI: 69.2–82.9 %) in HIV-positive men, with the highest prevalence of 87.5 % (7/8; 95 % CI: 50.8–99.9 %) in men 18–25 years of age. HPV prevalence was found to decrease with increasing age in HIV-negative men (P = 0.004), but not in HIV-positive men (P = 0.385). HIV-positive women had a significantly higher prevalence of one or more HPV type(s) in the bivalent (HPV-16/18: 20 % 55/277, 9 % 12/207; P <0.001), quadrivalent (HPV-6/11/16/18: 26 % 71/277, 12 % 24/207; P = 0.001) and nonavalent vaccine (HPV-6/11/16/18/31/33/52/56/58: 65 % 181/277, 24 % 50/207; P <0.001) compared to HIV-negative women. Similar observation were observed in men for bivalent (20 % 32/158, 10 % 30/313; P = 0.001), quadrivalent (35 % 56/158, 13 % 41/313; P <0.001) and nonavalent vaccine (75 % 119/158, 28 % 87/313; P <0.001). CONCLUSIONS: This study demonstrated high HPV prevalence among HIV-positive women and men in all age groups. The high prevalence of HPV types found in bivalent, quadrivalent and nonavalent vaccines in South African HIV-positive and HIV-negative women and men demonstrate that this population will greatly benefit from current HPV vaccines. BioMed Central 2015-10-26 /pmc/articles/PMC4624185/ /pubmed/26502723 http://dx.doi.org/10.1186/s12879-015-1181-8 Text en © Mbulawa et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mbulawa, Zizipho Z A
Coetzee, David
Williamson, Anna-Lise
Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title_full Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title_fullStr Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title_full_unstemmed Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title_short Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status
title_sort human papillomavirus prevalence in south african women and men according to age and human immunodeficiency virus status
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624185/
https://www.ncbi.nlm.nih.gov/pubmed/26502723
http://dx.doi.org/10.1186/s12879-015-1181-8
work_keys_str_mv AT mbulawaziziphoza humanpapillomavirusprevalenceinsouthafricanwomenandmenaccordingtoageandhumanimmunodeficiencyvirusstatus
AT coetzeedavid humanpapillomavirusprevalenceinsouthafricanwomenandmenaccordingtoageandhumanimmunodeficiencyvirusstatus
AT williamsonannalise humanpapillomavirusprevalenceinsouthafricanwomenandmenaccordingtoageandhumanimmunodeficiencyvirusstatus